Cargando…
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
BACKGROUND: Several new drugs are approved for treatment of patients with multiple myeloma (MM), but no validated biomarkers are available for the prediction of a clinical outcome. We aimed to establish whether pretreatment blood and bone marrow plasma concentrations of major cytokines and angiogeni...
Autores principales: | Saltarella, Ilaria, Morabito, Fortunato, Giuliani, Nicola, Terragna, Carolina, Omedè, Paola, Palumbo, Antonio, Bringhen, Sara, De Paoli, Lorenzo, Martino, Enrica, Larocca, Alessandra, Offidani, Massimo, Patriarca, Francesca, Nozzoli, Chiara, Guglielmelli, Tommasina, Benevolo, Giulia, Callea, Vincenzo, Baldini, Luca, Grasso, Mariella, Leonardi, Giovanna, Rizzo, Manuela, Falcone, Antonietta Pia, Gottardi, Daniela, Montefusco, Vittorio, Musto, Pellegrino, Petrucci, Maria Teresa, Dammacco, Franco, Boccadoro, Mario, Vacca, Angelo, Ria, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327520/ https://www.ncbi.nlm.nih.gov/pubmed/30626425 http://dx.doi.org/10.1186/s13045-018-0691-4 |
Ejemplares similares
-
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
por: D’Agostino, Mattia, et al.
Publicado: (2021) -
Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies
por: Reale, Antonia, et al.
Publicado: (2016) -
Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus
por: Mario, Boccadoro, et al.
Publicado: (2021) -
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
por: Larocca, Alessandra, et al.
Publicado: (2020) -
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)